Ardelyx, Inc. logo ARDX - Ardelyx, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 16
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $15.00 DETAILS
HIGH: $17.00
LOW: $13.00
MEDIAN: $15.00
CONSENSUS: $15.00
UPSIDE: 285.60%

Stock News

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ardelyx (ARDX)

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ardelyx (ARDX)

Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations

Aug 18, 2026 06:13 AM • globenewswire.com (Hide legal announcements)
ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)

ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)

NEW YORK--(BUSINESS WIRE)--Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company's second quarter report. If you held ARDX shares and lost money, you are encouraged to submit your loss information for review. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The damage came alongside numbers the Company itself called records. Arde.

Aug 17, 2026 06:09 AM • businesswire.com (Hide legal announcements)
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Ardelyx (NASDAQ: ARDX) shares closed at $4.00 on August 7, 2026, an 17.86% single-session decline, after the Company reported second quarter 2026 product revenue of $118.1 million and a loss of approximately $(0.07) per share -- both below consensus estimates.

Aug 13, 2026 06:44 PM • prnewswire.com (Hide legal announcements)
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force to convert demand into realized revenue.

Aug 12, 2026 12:52 AM • seekingalpha.com
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m.

Jul 23, 2026 04:01 AM • globenewswire.com
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026

WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026 on June 3 at 9:55 a.m. ET in New York.

May 19, 2026 04:01 AM • globenewswire.com
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National Kidney Foundation's (NKF) Spring Clinical Meetings, currently underway in New Orleans.

May 07, 2026 04:01 AM • globenewswire.com

Price Targets